Research programme: drug discovery - Genfit/Sanofi

Drug Profile

Research programme: drug discovery - Genfit/Sanofi

Alternative Names: SAN/GFT 2; SAVX1 programme

Latest Information Update: 19 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Genfit; sanofi-aventis
  • Developer Genfit; Sanofi
  • Class
  • Mechanism of Action Peroxisome proliferator-activated receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Atherosclerosis; Inflammation; Type 2 diabetes mellitus
  • Research Kidney disorders
  • Discontinued Neurodegenerative disorders

Most Recent Events

  • 19 Oct 2015 Early research in Kidney disorders in France (unspecified route)
  • 12 Apr 2012 Preclinical development is ongoing in France
  • 06 May 2011 Sanofi-aventis is now called Sanofi
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top